Silvia Gasperoni

6.3k total citations
32 papers, 508 citations indexed

About

Silvia Gasperoni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Silvia Gasperoni has authored 32 papers receiving a total of 508 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Silvia Gasperoni's work include Colorectal Cancer Treatments and Studies (11 papers), Gastric Cancer Management and Outcomes (11 papers) and Cancer Treatment and Pharmacology (9 papers). Silvia Gasperoni is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Gastric Cancer Management and Outcomes (11 papers) and Cancer Treatment and Pharmacology (9 papers). Silvia Gasperoni collaborates with scholars based in Italy, United States and United Kingdom. Silvia Gasperoni's co-authors include Francesco Di Costanzo, Paolo Carlini, Giancarlo Bisagni, Luca Moscetti, Annarosa Arcangeli, Luca Messerini, Roberto Labianca, B. Massidda, A. Iop and Enrico Cortesi and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Scientific Reports.

In The Last Decade

Silvia Gasperoni

29 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Silvia Gasperoni Italy 12 255 249 140 132 72 32 508
Eun‐Jung Jung South Korea 14 188 0.7× 180 0.7× 172 1.2× 80 0.6× 131 1.8× 23 559
Sietze T. van Turenhout Netherlands 15 228 0.9× 334 1.3× 241 1.7× 137 1.0× 72 1.0× 25 575
Georgios Ayiomamitis Greece 12 92 0.4× 214 0.9× 181 1.3× 51 0.4× 62 0.9× 22 411
Matthew M. Rochefort United States 13 175 0.7× 290 1.2× 141 1.0× 20 0.2× 84 1.2× 27 505
Sunao Moriguchi Japan 14 438 1.7× 154 0.6× 329 2.4× 133 1.0× 106 1.5× 17 642
Akiko Fujii Japan 12 215 0.8× 152 0.6× 86 0.6× 18 0.1× 158 2.2× 52 459
R. Brunet France 12 290 1.1× 458 1.8× 257 1.8× 47 0.4× 123 1.7× 30 727
Marco Filetti Italy 12 121 0.5× 158 0.6× 57 0.4× 26 0.2× 70 1.0× 38 319
Irmina A. Elliott United States 14 135 0.5× 278 1.1× 199 1.4× 19 0.1× 64 0.9× 37 472
José Dinis Portugal 11 127 0.5× 219 0.9× 226 1.6× 23 0.2× 47 0.7× 29 493

Countries citing papers authored by Silvia Gasperoni

Since Specialization
Citations

This map shows the geographic impact of Silvia Gasperoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Gasperoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Gasperoni more than expected).

Fields of papers citing papers by Silvia Gasperoni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Gasperoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Gasperoni. The network helps show where Silvia Gasperoni may publish in the future.

Co-authorship network of co-authors of Silvia Gasperoni

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Gasperoni. A scholar is included among the top collaborators of Silvia Gasperoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Gasperoni. Silvia Gasperoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Grazzini, Giulia, Diletta Cozzi, Ginevra Danti, et al.. (2021). Gastrointestinal stromal tumors: relationship between preoperative CT features and pathologic risk stratification. Tumori Journal. 107(6). 556–563. 13 indexed citations
3.
Nannini, Margherita, Alessandro Rizzo, Bruno Vincenzi, et al.. (2021). Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. ESMO Open. 6(4). 100222–100222. 7 indexed citations
4.
Roviello, Giandomenico, Martina Catalano, Alberto D’Angelo, et al.. (2020). Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Scientific Reports. 10(1). 19281–19281. 11 indexed citations
5.
Guerra, Francesco, et al.. (2018). Feasibility of robotic resection of gastrointestinal stromal tumors along the entire gastrointestinal tract. Updates in Surgery. 71(4). 695–700. 4 indexed citations
6.
Costanzo, Francesco Di, Silvia Gasperoni, Giancarlo Bisagni, et al.. (2008). Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. JNCI Journal of the National Cancer Institute. 100(6). 388–398. 94 indexed citations
7.
Costanzo, Francesco Di, Roberto Ravasio, Alberto Sobrero, et al.. (2008). Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukesʼ C Colon Cancer. Clinical Drug Investigation. 28(10). 645–655. 26 indexed citations
8.
Costanzo, Francesco Di, et al.. (2008). Circulating tumour cells in colorectal cancer. European Journal of Cancer Supplements. 6(14). 52–59. 2 indexed citations
9.
Gelibter, Alain, Teresa Gamucci, Francesco Di Costanzo, et al.. (2007). A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. Current Medical Research and Opinion. 23(9). 2117–2123. 13 indexed citations
10.
Costanzo, Francesco Di, Paolo Carlini, Laura Doni, et al.. (2005). Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). British Journal of Cancer. 93(2). 185–189. 78 indexed citations
11.
Costanzo, Francesco Di, Silvia Gasperoni, Paola Papaldo, et al.. (2005). Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. Annals of Oncology. 17(1). 79–84. 11 indexed citations
12.
Marinis, Filippo de, Maria Rita Migliorino, Luca Paoluzzi, et al.. (2003). Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer. Lung Cancer. 39(3). 331–338. 10 indexed citations
13.
Cocconi, Giorgio, Paolo Carlini, Alessandro Gamboni, et al.. (2003). Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Annals of Oncology. 14(8). 1258–1263. 54 indexed citations
14.
15.
Zeuli, Massimo, et al.. (2001). Capecitabine and oxaliplatin in advanced colorectal cancer: A dose-finding study. Annals of Oncology. 12(12). 1737–1741. 19 indexed citations
16.
Costanzo, Francesco Di, et al.. (2000). Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. Critical Reviews in Oncology/Hematology. 35(2). 101–108. 26 indexed citations
17.
Costanzo, Francesco Di, R Canaletti, N. Olmeo, et al.. (2000). Modulation of Fluorouracil by Methotrexate, Leucovorin, and Cisplatin (M-FLP) in the Treatment of Advanced Pancreatic Cancer. American Journal of Clinical Oncology. 23(3). 314–318. 4 indexed citations
18.
Costanzo, Francesco Di, et al.. (1999). Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. Breast Cancer Research and Treatment. 54(2). 165–171. 3 indexed citations
19.
Costanzo, Francesco Di, Silvia Gasperoni, P Malacarne, et al.. (1998). High-Dose Folinic Acid and 5-Fluorouracil Alone or Combined With Hydroxyurea in Advanced Colorectal Cancer. American Journal of Clinical Oncology. 21(4). 369–375. 9 indexed citations
20.
Tucci, A., O Varoli, Roberto Corinaldesi, et al.. (1993). Evaluation of Helicobacter pylori sensitivity to amoxycillin and metronidazole in dyspeptic patients.. PubMed. 25(2). 65–7. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eun‐Jung Jung Breakdown of academic impact, for papers by Sietze T. van Turenhout Breakdown of academic impact, for papers by Georgios Ayiomamitis Breakdown of academic impact, for papers by Matthew M. Rochefort Breakdown of academic impact, for papers by Sunao Moriguchi Breakdown of academic impact, for papers by Akiko Fujii Breakdown of academic impact, for papers by R. Brunet Breakdown of academic impact, for papers by Marco Filetti Breakdown of academic impact, for papers by Irmina A. Elliott Breakdown of academic impact, for papers by José Dinis
Rankless by CCL
2026